RU2018120938A - Композиции и способы, используемые для повышения и поддержания кетоза - Google Patents
Композиции и способы, используемые для повышения и поддержания кетоза Download PDFInfo
- Publication number
- RU2018120938A RU2018120938A RU2018120938A RU2018120938A RU2018120938A RU 2018120938 A RU2018120938 A RU 2018120938A RU 2018120938 A RU2018120938 A RU 2018120938A RU 2018120938 A RU2018120938 A RU 2018120938A RU 2018120938 A RU2018120938 A RU 2018120938A
- Authority
- RU
- Russia
- Prior art keywords
- beta
- hydroxybutyrate
- salt
- acid
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 28
- 208000007976 Ketosis Diseases 0.000 title claims 6
- 230000004140 ketosis Effects 0.000 title claims 6
- -1 beta-hydroxybutyrate compound Chemical class 0.000 claims 25
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 10
- 241000124008 Mammalia Species 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 8
- 150000002148 esters Chemical class 0.000 claims 6
- NBPUSGBJDWCHKC-DFWYDOINSA-M sodium;(3s)-3-hydroxybutanoate Chemical compound [Na+].C[C@H](O)CC([O-])=O NBPUSGBJDWCHKC-DFWYDOINSA-M 0.000 claims 6
- CINYGFCEISABSR-UHFFFAOYSA-M potassium;3-hydroxybutanoate Chemical compound [K+].CC(O)CC([O-])=O CINYGFCEISABSR-UHFFFAOYSA-M 0.000 claims 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 4
- 239000003240 coconut oil Substances 0.000 claims 4
- 235000019864 coconut oil Nutrition 0.000 claims 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 150000003626 triacylglycerols Chemical class 0.000 claims 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 230000036528 appetite Effects 0.000 claims 3
- 235000019789 appetite Nutrition 0.000 claims 3
- OXUQOKIBNYSTGF-UHFFFAOYSA-L calcium;3-hydroxybutanoate Chemical compound [Ca+2].CC(O)CC([O-])=O.CC(O)CC([O-])=O OXUQOKIBNYSTGF-UHFFFAOYSA-L 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 235000020197 coconut milk Nutrition 0.000 claims 3
- 235000013305 food Nutrition 0.000 claims 3
- ZIMQIJFHENOQDO-UHFFFAOYSA-L magnesium;3-hydroxybutanoate Chemical compound [Mg+2].CC(O)CC([O-])=O.CC(O)CC([O-])=O ZIMQIJFHENOQDO-UHFFFAOYSA-L 0.000 claims 3
- 239000000178 monomer Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- OMSUIQOIVADKIM-UHFFFAOYSA-N ethyl 3-hydroxybutyrate Chemical compound CCOC(=O)CC(C)O OMSUIQOIVADKIM-UHFFFAOYSA-N 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- QPQMKNGFJFUJNY-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;3-hydroxybutanoic acid Chemical compound CC(O)CC(O)=O.NCCCC[C@H](N)C(O)=O QPQMKNGFJFUJNY-JEDNCBNOSA-N 0.000 claims 1
- PGRNZHOQVAPMFX-WCCKRBBISA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N PGRNZHOQVAPMFX-WCCKRBBISA-N 0.000 claims 1
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims 1
- 108010011485 Aspartame Proteins 0.000 claims 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- 239000000619 acesulfame-K Substances 0.000 claims 1
- 125000000217 alkyl group Chemical class 0.000 claims 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims 1
- 239000000605 aspartame Substances 0.000 claims 1
- 229960003438 aspartame Drugs 0.000 claims 1
- 235000010357 aspartame Nutrition 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- 229960002173 citrulline Drugs 0.000 claims 1
- 235000013477 citrulline Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- RMYDGRIFARQXSJ-UHFFFAOYSA-M lithium;3-hydroxybutanoate Chemical compound [Li+].CC(O)CC([O-])=O RMYDGRIFARQXSJ-UHFFFAOYSA-M 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 229950006238 nadide Drugs 0.000 claims 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000003346 palm kernel oil Substances 0.000 claims 1
- 235000019865 palm kernel oil Nutrition 0.000 claims 1
- 239000004302 potassium sorbate Substances 0.000 claims 1
- 235000010241 potassium sorbate Nutrition 0.000 claims 1
- 229940069338 potassium sorbate Drugs 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 235000008160 pyridoxine Nutrition 0.000 claims 1
- 239000011677 pyridoxine Substances 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 229960002477 riboflavin Drugs 0.000 claims 1
- 235000019192 riboflavin Nutrition 0.000 claims 1
- 239000011833 salt mixture Substances 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 229960003885 sodium benzoate Drugs 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 229940011671 vitamin b6 Drugs 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (32)
1.Композиция для индуцирования и поддержания пищевого кетоза, содержащая:
как минимум одну среднецепочечную кислоту или ее эфир, и
как минимум одно соединение бета-гидроксибутирата, которое включает соль мономера бета-гидроксибутирата.
2. Композиция, для достижения кетоза у млекопитающих, содержащая:
как минимум одну среднецепочечную кислоту или ее эфир, и
минимум одно соединение бета-гидроксибутирата, которое включает мономер бета-гидроксибутирата или комбинацию мономера бета-гидроксибутирата и предшественника бета-гидроксибутирата.
3.Композиция, для применения в качестве лекарственного средства для индуцирования и поддержания пищевого кетоза, содержащая:
как минимум одну среднецепочечную кислоту или ее эфир, и
минимум одно соединение бета-гидроксибутирата, которое представляет собой смесь солей бета-гидроксибутирата.
4. Композиция, по любому из пп.1-3, в которой в качестве как минимум одного соединения бета-гидроксибутирата входит одно или несколько из перечисленных ниже веществ:
соль бета-гидроксибутирата, содержащая натриевую соль бета гидроксибутирата, аргининовую соль бета-гидроксибутирата, калиевую соль бета-гидроксибутирата, кальциевую соль бета-гидроксибутирата, магниевую соль бета-гидроксибутирата, литиевую соль бета-гидроксибутирата, лизиновую соль бета-гидроксибутирата, гистидиновую соль бета-гидроксибутирата, орнитиновую соль бета-гидроксибутирата, креатиновую соль бета-гидроксибутирата, агматиновую соль бета-гидроксибутирата или цитруллиновую соль бета-гидроксибутирата;
смесь солей, содержащая в себя множество натриевой соли бета-гидроксибутирата, калиевой соли бета-гидроксибутирата, кальциевой соли бета-гидроксибутирата, магниевой соли бета-гидроксибутирата; или комбинацию соли бета-гидроксибутирата и 1,3-бутандиола, соли бета-гидроксибутирата и этилацетоацетата, бета-гидроксибутирата и этил-бета-гидроксибутирата, смесь соли и 1,3-бутандиола, смесь соли и этилацетата, или смесь соли и этил-бета-гидроксибутирата.
5.Композиция, по любому из пп.1-3, в которой как минимум одно бета-гидрокси-соединение содержит:
натриевую соль бета-гидроксибутирата, аргининовую соль бета-гидроксибутирата или их комбинация, либо
комбинацию натриевой соли бета-гидроксибутирата и калиевой соли бета-гидроксибутирата.
6. Композиция, по любому из пп.1-3, в которой в качестве как минимум одного соединения бета-гидроксибутирата входит гистидиновая соль бета-гидроксибутирата, орнитиновая соль бета-гидроксибутирата, кератиновая соль бета-гидроксибутирата, агматиновая соль бета-гидроксибутирата или цитруллиновая соль бета-гидроксибутирата.
7. Композиция, по любому из пп.1-3, в которой как минимум одно соединение бета-гидроксибутирата представляет собой рацемический DL-бета-гидроксибутират или R-бета-гидроксибутират с одним изомером.
8. Композиция, по любому из пп.1-3, в которой как минимум одна среднецепочечная жирная кислота или её эфир выбраны из группы: среденецепочечные триглицериды, кокосовое масло, порошок кокосового молока, фракционированное кокосовое масло, пальмоядровое масло, изолированная капроновая кислота, изолированная октановая кислота или изолированная декановая кислота.
9. Композиция, по любому из пп.1-3, также включающая как минимум одну нетоксичную минеральную соль.
10.Композиция, по любому из пп.1-3, также включающая как минимум один компонент, выбранный из группы, включающей в себя следующие вещества: аминокислоты, метаболиты аминокислот, витамины, минералы, порошок кокосового молока, электролиты, никотинамидадениндинуклеотид, тетрагидробиопетерин, альфа-кетоглутаровая кислота, альфа-липоевая кислота, пищевые кофакторы, кальциевая соль бета-метил-бета-гидроксибутират, альфа-кетоглутарат аргинина, натриевая соль R-альфа-липоевой кислоты, рибофлавин, ниацин, пиридоксин, аскорбиновая кислота, лимонная кислота, яблочная кислота, бензоат натрия, сорбат калия, ацесульфам К, аспартам, ксантановая камед и комбинации указанных компонентов.
11. Композиция, по любому из пп.1-3, в которой как минимум одно соединение бета-гидроксибутирата выбрано из группы, включающей в себя следующие вещества: натриевая соль бета-гидроксибутирата, калиевая соль бета-гидроксибутирата, кальциевая соль бета-гидроксибутирата, магниевая соль бета-гидроксибутирата, аргининовая соль бета-гидроксибутирата, натриевая соль бета-гидроксибутирата и калиевая соль бета-гидроксибутирата, лизиновая соль бета-гидроксибутирата, гистидиновая соль бета-гидроксибутирата, орнитиновая соль бета-гидроксибутирата, креатиновая соль бета-гидроксибутирата, агматиновая соль бета-гидроксибутирата, цитруллиновая соль бета-гидроксибутирата и их комбинации.
12.Композиция, по любому из пп.1-3, в которой как минимум одна среднецепочечная жирная кислота или её эфир, выбрана из группы, включающей в себя следующие вещества: кокосовое масло, порошок кокосового молока, фракционированное кокосовое масло, изолированная капроновая кислота, изолированной октановой кислоты, изолированной декановая кислота, этоксилированный триглицерид, еноновые производные триглицеридов, альдегидные производные триглицеридов, производные моноглицеридов, производные диглицеридов, производные триглицеридов или алкиловых эфиров.
14. Способ для достижения кетоза у млекопитающих, включающий применение композиции по любому из пп. 1-3.
14. Способ для достижения кетоза у млекопитающих, включающий применение композиции по любому из пп. 1-3.
15. Способ, по п.14, в котором композиция применяется в течение периода от одной до двух недель, и в котором способ также включает ограничение потребления пациентами углеводов и белков.
16.Способ, по п.14 или 15, в котором композиция применяется один раз в сутки, два раза в сутки или три раза в сутки в зависимости от потребности пациента.
17.Способ подавления аппетита и/или усиления снижения массы тела у млекопитающих, включающий применение композиции, по любому из пп. 1-3.
18. Способ, по любому из пп.14-17, в котором млекопитающее является человеком.
19. Способ, по любому из пп.14-17, в котором млекопитающее не является человеком.
21. Применение композиции по п.20, где композиция применяется для подавления аппетита у млекопитающих.
21. Применение композиции по п.20, где композиция применяется для подавления аппетита у млекопитающих.
22. Применение композиции по п.20 или 21, где композиция применяется для усиления снижения массы тела у млекопитающих.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361803203P | 2013-03-19 | 2013-03-19 | |
| US61/803,203 | 2013-03-19 | ||
| US201461926664P | 2014-01-13 | 2014-01-13 | |
| US61/926,664 | 2014-01-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015136190A Division RU2659386C2 (ru) | 2013-03-19 | 2014-03-19 | Композиции и способы, используемые для повышения и поддержания кетоза |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018120938A true RU2018120938A (ru) | 2018-11-06 |
| RU2018120938A3 RU2018120938A3 (ru) | 2019-04-04 |
Family
ID=51581503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015136190A RU2659386C2 (ru) | 2013-03-19 | 2014-03-19 | Композиции и способы, используемые для повышения и поддержания кетоза |
| RU2018120938A RU2018120938A (ru) | 2013-03-19 | 2014-03-19 | Композиции и способы, используемые для повышения и поддержания кетоза |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015136190A RU2659386C2 (ru) | 2013-03-19 | 2014-03-19 | Композиции и способы, используемые для повышения и поддержания кетоза |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9138420B2 (ru) |
| EP (1) | EP2976073B1 (ru) |
| JP (2) | JP6491189B2 (ru) |
| KR (2) | KR20150130312A (ru) |
| CN (1) | CN105050594B (ru) |
| AU (2) | AU2014236004B2 (ru) |
| BR (1) | BR112015024186B1 (ru) |
| CA (1) | CA2902603C (ru) |
| CL (2) | CL2015002802A1 (ru) |
| CR (1) | CR20150579A (ru) |
| IL (2) | IL241316B (ru) |
| MX (2) | MX391526B (ru) |
| MY (1) | MY180761A (ru) |
| NZ (1) | NZ711433A (ru) |
| PE (1) | PE20151949A1 (ru) |
| PH (1) | PH12015501966A1 (ru) |
| RU (2) | RU2659386C2 (ru) |
| SG (2) | SG11201506780RA (ru) |
| WO (1) | WO2014153416A1 (ru) |
| ZA (1) | ZA201506387B (ru) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648952B1 (en) | 2003-06-03 | 2018-03-07 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| CA2922223C (en) | 2012-11-05 | 2021-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services And Human Services | Ketone bodies to protect tissues from damage by ionizing radiation |
| GB201304467D0 (en) | 2013-03-12 | 2013-04-24 | Tdeltas Ltd | Compound for use in protecting skin |
| BR112015023190A2 (pt) | 2013-03-14 | 2017-07-18 | Univ Florida | regulação de câncer com o uso de compostos e/ou dieta naturais |
| EP2984066B1 (en) | 2013-03-14 | 2017-02-01 | Oxford University Innovation Limited | Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate |
| GB201314127D0 (en) * | 2013-08-07 | 2013-09-18 | Tdeltas Ltd | Ketone body and ketone body ester for reducing muscle breakdown |
| KR20170003542A (ko) * | 2014-04-02 | 2017-01-09 | 유니버시티 오브 써던 캘리포니아 | 자가면역성 및 다발성 경화증 치료 |
| US11020372B2 (en) | 2015-03-24 | 2021-06-01 | University Of Florida Research Foundation, Incorporated | Dietary and natural product management of negative side effects of cancer treatment |
| HK1251450A1 (zh) * | 2015-06-26 | 2019-02-01 | 佛罗里达大学研究基金会有限公司 | 使用天然化合物和/或饮食治疗炎症的方法 |
| US10987340B2 (en) | 2015-07-24 | 2021-04-27 | Jesse Alexander Galinski | Composition and method for rapidly inducing an endogenous ketosis |
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10245242B1 (en) * | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US10245243B1 (en) | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10292952B2 (en) | 2016-03-11 | 2019-05-21 | Axcess Global Sciences, Llc | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US20170266147A1 (en) * | 2016-03-18 | 2017-09-21 | Csilla Ari D'Agostino | Methods of increasing latency of anesthetic induction using ketone supplementation |
| WO2017165443A1 (en) * | 2016-03-21 | 2017-09-28 | Csilla Ari D'agostino | Methods of improving motor function using ketone supplementation |
| US20190091189A1 (en) * | 2016-03-21 | 2019-03-28 | Csilla Ari D'Agostino | Administration of exogenous ketone to lower blood glucose |
| US10376482B2 (en) | 2016-04-03 | 2019-08-13 | Franco Cavaleri | Butyrate and beta-hydroxybutyrate compositions |
| US12208074B2 (en) | 2016-04-03 | 2025-01-28 | Franco Cavaleri | Butyrate and beta-hydroxybutyrate compositions |
| WO2017184789A1 (en) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| CA3021784A1 (en) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US11337945B2 (en) | 2016-06-01 | 2022-05-24 | Keto Innovations, Llc | C5 ketone compositions, and related methods, for therapeutic and performance supplementation |
| AU2017278099B2 (en) | 2016-06-07 | 2021-03-11 | Ithaca College | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
| US10588877B2 (en) | 2016-07-21 | 2020-03-17 | Savind, Inc. | Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same |
| JP6935994B2 (ja) * | 2016-08-19 | 2021-09-15 | 株式会社明治 | ケトン体生成促進用組成物 |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| US11297873B2 (en) | 2016-09-13 | 2022-04-12 | Abbott Laboratories | Ketogenic nutritional compositions |
| WO2018081118A1 (en) * | 2016-10-24 | 2018-05-03 | University Of South Florida | Delaying latency to seizure by combinations of ketone supplements |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US9925164B1 (en) * | 2017-01-12 | 2018-03-27 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
| CN110392547A (zh) * | 2017-03-08 | 2019-10-29 | 雅培糖尿病护理公司 | 使用分析数据进行健康和营养监测和管理的系统、装置和方法 |
| EP3598897A4 (en) * | 2017-03-28 | 2021-01-13 | Lonza Solutions AG | WATER-SOLUBLE ANTIBACTERIAL COMPOSITION |
| JP6968624B2 (ja) * | 2017-04-06 | 2021-11-17 | 株式会社明治 | ケトン食摂取量の管理方法 |
| US11249087B2 (en) | 2017-04-06 | 2022-02-15 | Meiji Co., Ltd. | Device for monitoring effective state of ketogenic diet |
| WO2018187852A1 (en) * | 2017-04-12 | 2018-10-18 | Cavaleri Franco | Butyrate and beta-hydroxybutyrate compositions and methods of use thereof |
| US12171735B2 (en) | 2017-04-19 | 2024-12-24 | Axcess Global Sciences, Llc | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| US20200129463A1 (en) * | 2018-10-29 | 2020-04-30 | Keto Patent Group, Inc. | Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans |
| CN107083406B (zh) * | 2017-05-27 | 2021-02-02 | 浙江华睿生物技术有限公司 | (r)-3-羟基丁酸的生产方法 |
| GB201710229D0 (en) | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
| IL272173B2 (en) | 2017-07-21 | 2025-06-01 | Buck Inst Res Aging | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same |
| CN109394745A (zh) * | 2017-08-17 | 2019-03-01 | 博瑞生物医药（苏州）股份有限公司 | 一种包含左旋肉碱和β-羟基丁酸化合物的组合物 |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| GB201715654D0 (en) * | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| US20190119705A1 (en) * | 2017-10-20 | 2019-04-25 | KetoneAid Inc. | Substantially non-racemic ketone ester of beta hydroxybutyrate and production process thereof |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| WO2019118624A1 (en) * | 2017-12-12 | 2019-06-20 | University Of South Florida | Compositions and methods for weight loss maintenance |
| KR20200131810A (ko) * | 2018-01-05 | 2020-11-24 | 텍사스 테크 유니버시티 오피스 오브 리서치 커머셜라이제이션 | 간헐적 금식과 관련된 β-하이드록시-β-메틸부티레이트 (HMB)의 조성물 및 사용 방법 |
| US12037317B2 (en) | 2018-01-25 | 2024-07-16 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| CN118453508A (zh) * | 2018-02-01 | 2024-08-09 | 维尔斯达医疗公司 | 包含尿苷的药物组合物及其应用以及用于递送尿苷的系统 |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US20200061023A1 (en) * | 2018-08-27 | 2020-02-27 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11484542B2 (en) | 2018-05-30 | 2022-11-01 | Adam Slank | Specialized tongue spray containing gymnemic acid and exogenous ketones |
| WO2019234628A1 (en) * | 2018-06-07 | 2019-12-12 | Société des Produits Nestlé S.A. | Methods and compositions for increasing ketone bodies in animals |
| CA3022995C (en) | 2018-06-12 | 2019-10-15 | Ketofibe (9211-3133 Quebec Inc.) | Novel ketogenic compounds, compositions, methods and use thereof |
| BR112020022985A2 (pt) * | 2018-06-21 | 2021-02-02 | Société des Produits Nestlé S.A. | composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona |
| US12419852B2 (en) | 2018-08-27 | 2025-09-23 | Exerkine Corporation | Method for treating lysosomal storage disease |
| US20200068939A1 (en) * | 2018-09-04 | 2020-03-05 | Jho Intellectual Property Holdings Llc | Nutritional compositions to increase and sustain blood ketone levels |
| SG11202102204PA (en) | 2018-09-25 | 2021-04-29 | Ponce De Leon Health Designated Activity Company | Process of making calcium alpha-ketoglutarate |
| GB2577723A (en) | 2018-10-04 | 2020-04-08 | Tdeltas Ltd | Compounds for new use |
| US20210338613A1 (en) * | 2018-10-05 | 2021-11-04 | Dyve Biosciences, Inc. | Formulations and methods for transdermal administration of ketones |
| CN109480284A (zh) * | 2018-12-05 | 2019-03-19 | 上海欣海生物科技有限公司 | 一种生酮食品及其制备方法 |
| CN113194733A (zh) * | 2018-12-18 | 2021-07-30 | 雀巢产品有限公司 | 混合的甘油三酯 |
| CN109734575A (zh) * | 2019-01-04 | 2019-05-10 | 上海欣海国际贸易有限公司 | 一种制备3-羟基丁酸氨基酸盐复合物的方法 |
| AU2020221916B2 (en) * | 2019-02-11 | 2025-08-07 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| JP2022520560A (ja) * | 2019-02-11 | 2022-03-31 | アクセス・グローバル・サイエンシーズ・エルエルシー | ベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法 |
| AU2020221569B2 (en) * | 2019-02-11 | 2025-06-26 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| WO2020180980A1 (en) * | 2019-03-04 | 2020-09-10 | Cerecin Inc. | Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto |
| EP4595775A3 (en) * | 2019-03-14 | 2025-10-22 | The Regents of the University of California | Bhb-citrate combination products for renal health and treating disease |
| JP7281927B2 (ja) * | 2019-03-14 | 2023-05-26 | 大阪瓦斯株式会社 | 心拍数低減剤 |
| EP3941455A1 (en) * | 2019-03-22 | 2022-01-26 | Société des Produits Nestlé S.A. | Methods using administration of medium chain triglycerides (mct) prior to a meal to increase ketone production from the mcts |
| AU2020247196B2 (en) * | 2019-03-22 | 2025-11-13 | Société des Produits Nestlé S.A. | Methods using medium chain triglycerides administered prior to a meal to decrease postprandial glucose from the meal |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| EP3956283A1 (de) * | 2019-06-12 | 2022-02-23 | IOI Oleo GmbH | Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren |
| CN113993833B (zh) * | 2019-06-12 | 2024-05-10 | 凯托利皮克斯治疗有限责任公司 | 酰基封端的3-羟基羧酸及其盐和酯的生产方法 |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11915605B2 (en) | 2019-10-17 | 2024-02-27 | Nicolas Tzenios | Ketogenic diet recommendation to a user based on a blood low-density lipoprotein (LDL) level and a blood C-reactive protein level and/or a blood erythrocyte sedimentation rate (ESR) thereof |
| WO2021150928A1 (en) * | 2020-01-23 | 2021-07-29 | University Of South Florida | Prevention and treatment of effects of aging and age-associated disorders with ketone supplementation |
| BR112022017809A2 (pt) | 2020-03-05 | 2023-01-10 | Vitanav Inc | Composição de ácido (d)-ss-hidroxibutírico, ácido (d)-ss-hidroxivalérico e (d)-1,3-butanodiol como suplemento nutricional e agente terapêutico |
| WO2021195477A1 (en) | 2020-03-27 | 2021-09-30 | Ketoneaid, Inc. | Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections |
| JP2023529504A (ja) * | 2020-06-14 | 2023-07-10 | エル－ニュートラ・インコーポレイテッド | ファスティング状態を維持及び延長する断続的なファスティングバー／ドリンク |
| US20230255912A1 (en) * | 2020-07-02 | 2023-08-17 | Ponce De Leon Health Designated Activity Company | Compositions and methods for treating crp-mediated diseases |
| US12186297B2 (en) * | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| CN112137115A (zh) * | 2020-09-25 | 2020-12-29 | 深圳市捷利康生物科技有限公司 | 具有增强免疫力功效的生酮营养粉及其制备方法 |
| US20240180891A1 (en) * | 2020-12-22 | 2024-06-06 | Buck Institute For Research On Aging | Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies |
| US20240190803A1 (en) * | 2021-04-16 | 2024-06-13 | Nanjing Nutrabuilding Bio-Tech Co., Ltd. | Low-lead and low-arsenic beta-hydroxybutyrate salts and methods for producing the same |
| US20240197659A1 (en) * | 2021-04-26 | 2024-06-20 | University Of South Florida | Methods for treating symptoms of kabuki syndrome |
| RU2769242C1 (ru) * | 2021-06-16 | 2022-03-29 | Александр Владимирович Чемоданов | Кетогенная композиция |
| CA3223325A1 (en) | 2021-06-28 | 2023-01-05 | Roberto Vianna Nonato | Methods to produce therapeutic formulations comprising hydroxybutirate and hydroxyvalerate, therapeutic formulations and uses thereof |
| WO2023043797A1 (en) | 2021-09-15 | 2023-03-23 | Abbott Diabetes Care Inc. | Systems, devices, and methods for applications for communication with ketone sensors |
| WO2023112818A1 (ja) * | 2021-12-14 | 2023-06-22 | サントリーホールディングス株式会社 | 炭酸飲料及び炭酸飲料の炭酸感を増強する方法 |
| CN118382365A (zh) * | 2021-12-14 | 2024-07-23 | 三得利控股株式会社 | 含有3羟基丁酸及低级脂肪族醇的饮料及呈味改善方法 |
| CN114306308A (zh) * | 2021-12-24 | 2022-04-12 | 苏州麦轮生物科技有限公司 | 一种含有酮酯的营养补充剂及其应用 |
| US12023382B2 (en) | 2022-01-18 | 2024-07-02 | Today Inc. | Molecules, formulations, and methods for nutritional support of athletes, patients, and others |
| WO2023139357A1 (en) * | 2022-01-18 | 2023-07-27 | Today Inc. | Molecules, nutritional formulations, and methods of providing nutritional support |
| JP7223193B1 (ja) | 2022-05-26 | 2023-02-15 | 大阪瓦斯株式会社 | 内臓脂肪低減剤およびその用途 |
| CN115192603B (zh) * | 2022-07-06 | 2023-04-21 | 西北农林科技大学 | 锂盐在制备防治奶牛酮病制剂中的应用 |
| CN115251375A (zh) * | 2022-07-11 | 2022-11-01 | 珠海麦得发生物科技股份有限公司 | 一种(r)-3-羟基丁酸生酮产品及其制备方法 |
| US12059398B2 (en) | 2022-08-26 | 2024-08-13 | Health Via Modern Nutrition Inc. | Compositions of 1,3-butanediol and beta-hydroxybutyric acid to provide optimal therapeutic ketosis |
| WO2025054130A1 (en) | 2023-09-05 | 2025-03-13 | The Regents Of The University Of California | Enzymes for oxidizing beta-hydroxybutyrate (bhb), test strips, and sensors of using the same |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8803141L (sv) * | 1988-09-07 | 1990-03-08 | Kabivitrum Ab | Naeringsmedel foer maenniskor och djur |
| US5654266A (en) * | 1992-02-10 | 1997-08-05 | Chen; Chung-Ho | Composition for tissues to sustain viability and biological functions in surgery and storage |
| EP2283834B1 (en) * | 1997-03-17 | 2016-07-13 | BTG International Limited | Therapeutic compositions comprising ketone bodies or their precursors |
| US6316038B1 (en) | 1997-03-17 | 2001-11-13 | Btg International Limited | Therapeutic compositions |
| US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| US20090253781A1 (en) | 2002-05-24 | 2009-10-08 | Btg International Limited | Therapeutic compositions |
| JPH1160434A (ja) | 1997-08-12 | 1999-03-02 | Kanebo Ltd | 皮膚老化防止化粧料 |
| ATE283056T1 (de) | 1998-07-22 | 2004-12-15 | Metabolix Inc | Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere |
| DE69935799T2 (de) | 1998-09-15 | 2007-12-27 | Btg International Ltd. | Therapeutische zusammenstellungen |
| TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| US20020006959A1 (en) | 2000-05-01 | 2002-01-17 | Henderson Samuel T. | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism |
| US6613356B1 (en) | 2000-10-10 | 2003-09-02 | Victor Vlahakos | Weight loss medication and method |
| US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| US8158184B2 (en) * | 2004-03-08 | 2012-04-17 | Bunge Oils, Inc. | Structured lipid containing compositions and methods with health and nutrition promoting characteristics |
| GB0410266D0 (en) * | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
| GB0420856D0 (en) | 2004-09-20 | 2004-10-20 | Ketocytonyx Inc | Cns modulators |
| US20070135376A1 (en) * | 2005-06-20 | 2007-06-14 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| KR101634083B1 (ko) * | 2006-04-03 | 2016-06-28 | 액세라인크 | 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도 |
| US7807718B2 (en) | 2006-06-30 | 2010-10-05 | Sami A. Hashim | Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose |
| US9186340B2 (en) * | 2007-04-12 | 2015-11-17 | Regents Of The University Of Minnesota | Ischemia/reperfusion protection compositions and methods of using |
| AU2009204370B2 (en) * | 2008-01-04 | 2014-12-04 | Gvmt Of The Usa, As Represented By The Secretary, Department Of Health & Human Services | Ketone bodies and ketone body esters as blood lipid lowering agents |
| GB201002983D0 (en) * | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| GB201206192D0 (en) | 2012-04-05 | 2012-05-23 | Tdeltas Ltd | Ketone bodies and ketone body esters and for maintaining or improving muscle power output |
-
2014
- 2014-03-19 SG SG11201506780RA patent/SG11201506780RA/en unknown
- 2014-03-19 CA CA2902603A patent/CA2902603C/en active Active
- 2014-03-19 JP JP2016504350A patent/JP6491189B2/ja active Active
- 2014-03-19 MX MX2019010248A patent/MX391526B/es unknown
- 2014-03-19 RU RU2015136190A patent/RU2659386C2/ru active
- 2014-03-19 SG SG10201808690PA patent/SG10201808690PA/en unknown
- 2014-03-19 MY MYPI2015703228A patent/MY180761A/en unknown
- 2014-03-19 WO PCT/US2014/031237 patent/WO2014153416A1/en not_active Ceased
- 2014-03-19 AU AU2014236004A patent/AU2014236004B2/en active Active
- 2014-03-19 RU RU2018120938A patent/RU2018120938A/ru not_active Application Discontinuation
- 2014-03-19 PE PE2015002047A patent/PE20151949A1/es unknown
- 2014-03-19 KR KR1020157025528A patent/KR20150130312A/ko not_active Ceased
- 2014-03-19 NZ NZ711433A patent/NZ711433A/en unknown
- 2014-03-19 CN CN201480016818.0A patent/CN105050594B/zh active Active
- 2014-03-19 BR BR112015024186-7A patent/BR112015024186B1/pt not_active IP Right Cessation
- 2014-03-19 KR KR1020227001002A patent/KR102499654B1/ko active Active
- 2014-03-19 EP EP14770025.6A patent/EP2976073B1/en active Active
- 2014-03-19 MX MX2015013312A patent/MX371259B/es active IP Right Grant
- 2014-08-08 US US14/455,385 patent/US9138420B2/en active Active
-
2015
- 2015-09-01 ZA ZA2015/06387A patent/ZA201506387B/en unknown
- 2015-09-04 PH PH12015501966A patent/PH12015501966A1/en unknown
- 2015-09-08 IL IL241316A patent/IL241316B/en active IP Right Grant
- 2015-09-17 CL CL2015002802A patent/CL2015002802A1/es unknown
- 2015-09-21 US US14/860,092 patent/US9675577B2/en active Active
- 2015-10-19 CR CR20150579A patent/CR20150579A/es unknown
-
2017
- 2017-06-01 US US15/610,668 patent/US10646462B2/en active Active
-
2018
- 2018-04-17 CL CL2018000983A patent/CL2018000983A1/es unknown
- 2018-05-21 IL IL259502A patent/IL259502B/en not_active IP Right Cessation
- 2018-12-04 JP JP2018227049A patent/JP2019031578A/ja active Pending
-
2019
- 2019-01-25 AU AU2019200511A patent/AU2019200511A1/en not_active Abandoned
-
2020
- 2020-05-11 US US16/871,686 patent/US20200268701A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018120938A (ru) | Композиции и способы, используемые для повышения и поддержания кетоза | |
| HRP20200068T1 (hr) | Etilni ester ikozapentaenske kiseline, namijenjen liječenju hipertrigliceridemije | |
| NZ727980A (en) | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | |
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| JP2015510888A5 (ru) | ||
| PH12016500100A1 (en) | Self-emulsifying composition of omega3 fatty acid | |
| MX2021002553A (es) | Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
| JP2015514104A5 (ru) | ||
| RU2015143112A (ru) | Способ лечения болезни паркинсона | |
| EP4556073A3 (en) | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy | |
| JP2013515742A5 (ru) | ||
| RU2013146517A (ru) | Композиции и способы, пригодные для облегчения возрастных заболеваний | |
| HRP20160203T1 (hr) | Pripravci koji sadrže 15-hepe i postupci njihove upotrebe | |
| JP2016511753A5 (ru) | ||
| RU2012139658A (ru) | Композиции и способы для доставки питательных веществ | |
| Özparlak | Effect of seasons on fatty acid composition and n-3/n-6 ratios of muscle lipids of some fish species in Apa Dam Lake, Turkey | |
| MX373270B (es) | Composiciones y metodos para mejorar el rendimiento del ejercicio. | |
| CN102579413A (zh) | 油酰乙醇胺及其衍生物的新用途 | |
| RU2016116835A (ru) | Способы и композиции для улучшения функции почек | |
| RU2005132004A (ru) | Стабилизированные композиции для местного применения, содержащие кетопрофен | |
| RU2006143803A (ru) | Применение альфа-кетоглутарата и родственных соединений для снижения липидов плазмы | |
| RU2016115374A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты | |
| RU2014122856A (ru) | Устойчивые составы антитромбоцитарных средств, омега-3 жирных кислот и амилозы в мягких желатиновых капсулах | |
| RU2016115375A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты | |
| RU2016115376A (ru) | Фармацевтические композиции, содержащие антибактериальные агенты |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20191025 |